CNCR Loncar Cancer Immunotherapy ETF
- 15.800
- -0.310-1.92%
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Market-Moving News for September 16th
ITeos Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target
Acrivon Therapeutics Analyst Ratings
Nuvation Bio Analyst Ratings
Summit Therapeutics Analyst Ratings
Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Reported Saturday, Nuvation Bio Announces Pooled Data From TRUST-I And TRUST-II Studies, Highlighting Taletrectinib's Best-In-Class Potential For Advanced ROS1-Positive NSCLC
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
Reported Saturday, Acrivon Therapeutics Reports ACR-368 Phase 2 Endometrial Cancer Data At ESMO, Advances ACR-2316 Ahead Of Schedule, And Updates On AP3 Interactome Progress
The increase within the year reached 1123%! The cooperation between Chinese and American pharmaceutical companies defeated the "global pharmaceutical king", and the CEO said straightforwardly, "We are on the right side".
Summit Pharmaceuticals has surpassed the global drug king pembrolizumab from China's pharmaceutical company Akeso with its new drug Yervoy (PD-1/VEGF bispecific antibody) in a head-to-head clinical trial.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Trending Stocks This Week as Market Bounces Back From Selloff
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Summit Boosts Instil, BioNTech as Lead Drug Beats Merck's Keytruda
Summit Therapeutics Shares Are Trading Higher After the Company on Thursday Announced It Raised $235 Million in Net Proceeds.
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today